Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intratympanic dexamethasone to prevent cisplatin-induced hearing loss
2015-003953-16Phase 3Completed
- Sponsor
- Área de Atención Integrada de Albacete
- Start
- Feb 2016
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of dexamethasone in cisplatin-induced ototoxicity, ototoxicity, Hypoacusis and 1 more, sponsored by Área de Atención Integrada de Albacete. Primary endpoint: Change in liminal tonal audiometry (pure tone audiometry) thresholds. Started Feb 2016; status: completed.
02
Drugs
dexamethasone
03
Conditions
cisplatin-induced ototoxicityototoxicityHypoacusistinnitus
Beyond the preview
Go deeper on 2015-003953-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-003953-16.